

PRESS RELEASE

Dornier MedTech Announces Presentation of Three Posters at American Urology Association 2018

San Francisco, 18 May 2018 – Dornier MedTech (Dornier), a global leader in innovative kidney stone management, today announced the presentation of three posters at the American Urology Association Annual Meeting taking place in San Francisco on 18 – 21 May 2018.

During the meeting, new data will be presented on the utilization of big data to evaluate outcomes of extracorporeal shockwave lithotripsy treatment of urological stones by Dornier's partner, Translational Analytics and Statistics. Results from a cross validation study of 3,894 treatment records of renal and ureteral stones show that Dornier's novel analytic algorithm, which uses historical detailed patient and stone characteristics and intraoperative treatment parameters, can assist physicians in making informed treatment choices which could translate to better clinical, evidence-based decision-making and patient outcomes.

Dornier MedTech will also be presenting two posters on holmium laser lithotripsy for the treatment of urological stones.

"Dornier is committed to establishing a growing body of clinical evidence that demonstrates its continued commitment to clinical leadership in urology," said Abel Ang, President and CEO of Dornier MedTech. "As the global market leader in urological disease treatment, we understand the need for urologists to make evidence-based decisions on the most effective treatment modalities. We are proud to be the first and only company to utilize big data and analytics to assist urologists in optimizing treatment protocols and, ultimately, patient outcomes. This is a key step in using precision medicine in treating kidney stones."

Details of the poster presentations are below:

Title: Cross validation of an updated predictive analytic model which predicts success and minimize complications of shockwave lithotripsy in the treatment of urinary stones

Date/Time: Friday, 18 May, 10:10 am – 10:20 am

Location: MCC WEST, 3018

Title: Does the laser pulse shape influence the treatment rate of stones?

Date/Time: Sunday, 20 May, 9:30 am – 11:30 am

Location: MCC WEST, 3004



Title: Holmium laser lithotripsy for ureteral and renal stones: is dusting equivalent to

fragmenting?

Date/Time: Sunday, 20 May, 9:30 am - 11:30 am

Location: MCC WEST, 3004

The publication abstracts are accessible online at *The Journal of Urology*: http://www.jurology.com/issue/S0022-5347(18)X0002-0

Ends

Media Contact:

Kelly Westermann +1 (404) 989-0498 kwestermann@dornier.com

About Dornier MedTech

Dornier MedTech is headquartered in Munich, Germany, and is a full subsidiary of Accuron MedTech. Dornier is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians, healthcare providers and research groups involved in urological care. As pioneers of the lithotripsy and a variety of surgical lasers, Dornier's 40 years of innovation and service has made it one of the most trusted MedTech companies in the industry.